echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express Precision Therapy has been approved by the FDA to expand its indications, and Cornerstone has rights in Greater China

    Express Precision Therapy has been approved by the FDA to expand its indications, and Cornerstone has rights in Greater China

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Blueprint Medicines announced today that the U.



    AYVAKIT (avapritinib) is a kinase inhibitor that has been approved by the FDA for the treatment of adult patients with gastrointestinal stromal tumors (GIST) who carry PDGFRA exon 18 mutations, including PDGFRA D842V mutations



    Mr.


    Reference: [1] FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis.


    Reference: [1] FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
    .
    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.